Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

@article{Freedman2009PlacebocontrolledPI,
  title={Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.},
  author={Arnold Stephen Freedman and Sattva S. Neelapu and Craig J Nichols and Michael J. Robertson and Benjamin Djulbegovic and Jane N. Winter and John Bender and Daniel P. Gold and Richard G. Ghalie and Morgan E Stewart and Vanessa Esquibel and Paul Hamlin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 18},
  pages={3036-43}
}
PURPOSE To evaluate patient-specific immunotherapy with mitumprotimut-T (idiotype keyhole limpet hemocyanin [Id-KLH]) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in CD20(+) follicular lymphoma. PATIENTS AND METHODS Patients with treatment-naive or relapsed/refractory disease achieving a complete response (CR), partial response (PR), or stable disease (SD) with four weekly rituximab infusions were randomly assigned to mitumprotimut-T/GM-CSF or placebo/GM-CSF, with doses given… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Lymphoma Immunotherapy: Current Status

View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…